1. Home
  2. SII vs ARQT Comparison

SII vs ARQT Comparison

Compare SII & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

HOLD

Current Price

$146.92

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$22.59

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SII
ARQT
Founded
2008
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
3.3B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
SII
ARQT
Price
$146.92
$22.59
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$132.00
$31.86
AVG Volume (30 Days)
221.6K
1.2M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
0.95%
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
N/A
$376,072,000.00
Revenue This Year
$26.22
$34.46
Revenue Next Year
$11.39
$29.77
P/E Ratio
$63.42
N/A
Revenue Growth
N/A
91.34
52 Week Low
$39.33
$11.86
52 Week High
$169.63
$31.77

Technical Indicators

Market Signals
Indicator
SII
ARQT
Relative Strength Index (RSI) 49.62 35.49
Support Level $79.37 $22.56
Resistance Level $167.47 $27.26
Average True Range (ATR) 7.71 1.24
MACD -2.60 -0.26
Stochastic Oscillator 7.65 2.22

Price Performance

Historical Comparison
SII
ARQT

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: